Your session is about to expire
← Back to Search
Botensilimab and Balstilimab for Colorectal Cancer
Study Summary
This trial aims to study different combinations of immunotherapy in colorectal cancer patients with liver metastases who are undergoing surgery to remove the tumors. The trial will investigate if these immunotherapy combinations can change the
Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
Are there any current openings for participants in this ongoing trial?
"As per information from clinicaltrials.gov, this particular study is presently not seeking participants. While it was first listed on 3/1/2024 and last updated on 2/29/2024, there are currently 1849 other trials actively recruiting patients."
Have Botensilimab and Balstilimab received FDA endorsement for use in patients?
"Based on our assessment at Power, the safety rating for Botensilimab and Balstilimab is set at 2. This evaluation is influenced by the ongoing Phase 2 trial which has generated preliminary safety data without confirming efficacy yet."
Share this study with friends
Copy Link
Messenger